Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 30, 2017
Pharmacy Choice - News - Pharmaceutical Development - March 30, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/31/15 - Araim Pharmaceuticals announces a strategic partnership with Vault Bioventures to support development and commercialization of ARA 290 as well as other peptides within a novel family
Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies. This new strategic collaboration is expected to leverage the expertise of Araim Pharmaceuticals in.
12/31/15 - Basilea provides clinical program updates
Release date- 28122015- Basilea Pharmaceutica Ltd. today provided an update on the planned clinical phase 3 development program for its antibiotic ceftobiprole in the United States and reported completion of patient recruitment and interim data from the ongoing phase 1/ 2 a study with the intravenous formulation of its oncology drug candidate BAL10
12/31/15 - Braeburn Pharmaceuticals and Camurus enroll first patient in a phase 3 efficacy trial of long-acting treatment for opioid dependence [Tripoli Post, The (Libya)]
-Princeton, New Jersey and Lund, Sweden 30 December 2015 Braeburn. Pharmaceuticals and Camurus announce that the first patient has been randomized. in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent.
12/31/15 - Clovis Oncology Receives Notification of PDUFA Extension for Rociletinib
By a News Reporter-Staff News Editor at Politics& Government Week Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for Clovis' New Drug Application for rociletinib by the standard extension period of three months with the new goal date of June 28, 2016. Clovis Oncology
12/31/15 - FDA awards stem cell co Pluristem orphan drug status [Globes, Tel Aviv, Israel]
Dec. 31 Israeli placenta-based cell therapy developer Pluristem Therapeutics Ltd. has been awarded orphan drug status by the US Food and Drug Administration for its PLX-PAD cells treatment for severe preeclampsia. We are encouraged by the US FDA designation that demonstrates Pluristem's commitment to the program and the potential promise it holds
12/31/15 - Global Blood Therapeutics Receives FDA Orphan Drug Designation for GBT440 in Sickle Cell Disease
Global Blood Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, announced today that the U.S. Food and Drug Administration has granted orphan drug designation for GBT440 for the treatment of patients with sickle cell disease.
12/31/15 - Industry-financed clinical trials on the rise, as number of NIH-funded trials falls
By a News Reporter-Staff News Editor at Politics& Government Week Since 2006, the number of industry-sponsored clinical trials studying the benefits and harms of medical treatments has risen dramatically, while the number of clinical trials funded by the National Institutes of Health has fallen substantially, according to new Johns Hopkins Bloomb
12/31/15 - LifeSci Capital Initiates Coverage of TetraLogic Pharmaceuticals Corporation
NEW YORK, NY/ ACCESSWIRE/ December 31, 2015/ LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of TetraLogic Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for cancer and infectious diseases.
12/31/15 - Market Overview on Deep Brain Stimulators - Medical Devices Pipeline Assessment, 2015, Medical Market Research, Trends and Forecast to Dominate Industry
The Report Deep Brain Stimulators- Medical Devices Pipeline Assessment, 2015 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.Albany, NY 12/31/2015 MarketResearchReports.Biz presents this most up-to-date research on "Deep Brain Stimulators- Medical Devices Pipeline Assessme
12/31/15 - Market Overview on Proliferative Vitreoretinopathy (PVR) Global Clinical Trials Review, H2, 2015, Industry Analysis, Market Forecast to Dominate Pharma Industry
The Report Proliferative Vitreoretinopathy Global Clinical Trials Review, H2, 2015 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.Albany, NY 12/31/2015 MarketResearchReports.Biz presents this most up-to-date research on "Proliferative Vitreoretinopathy Global Clinical...
12/31/15 - NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinsons Disease [Daily Tribune (Bahrain)]
-NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in a first efficacy trial of ND0612H, the companys continuously administered subcutaneous levodopa/carbidopa solution. This treatment is intended to be an alternative to current treatments..
12/31/15 - PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs [Arab News (Saudi Arabia)]
-PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today a shareholder update on PharmaCytes pancreatic cancer and diabetes programs. Manuel Hidalgo, and experts at Translational Drug...
12/31/15 - PLURISTEM THERAPEUTICS INC FILES (8-K) Disclosing Other Events
On December 31, 2015, the registrant announced that the U.S. Food and Drug Administration has granted the registrant's PLX-PAD cells Orphan Drug Designation in the treatment of severe preeclampsia.
12/31/15 - Researchers Submit Patent Application, "Method of Treating an Ocular Disease and Compositions Effective for Treating an Ocular Disease", for Approval...
Researchers Submit Patent Application, "Method of Treating an Ocular Disease and Compositions Effective for Treating an Ocular Disease", for Approval. By a News Reporter-Staff News Editor at Women's Health Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors Karla, Pradeep K.; Mangat, Harpal S., filed
12/31/15 - Rfa fibre for bipolar intraluminal application for varicose veins detail specification :us fda/european ce approved quality. inclusive of rental and... [TendersInfo (India)]
Tenders are invited for Rfa Fibre For Bipolar Intraluminal Application For Varicose Veins Detail Specification: Us Fda/ European Ce Approved Quality. Instructions/Remarks: All The Firms Participating In E-Tender Enquiry To Upload The Details Of The Offered Item In The Form Of Scanned Copy Of The Photo Of The Offered Item Showing All Relevant Detail
12/31/15 - Roche Submits Anti-Mullerian Hormone Assay for FDA Approval
By a News Reporter-Staff News Editor at Women's Health Weekly Roche announced that it has filed a direct de novo application to the U.S. Food and Drug Administration for a fully automated Anti-Mullerian assay for use on Roche's full portfolio of laboratory analyzers. Alan Wright, Chief Medical Officer, Roche Diagnostics Corporation. The assay is
12/31/15 - Teligent, Inc. Announces Fourteenth & Fifteenth ANDA Submissions Of 2015
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has submitted its fourteenth and fifteenth abbreviated new drug applications to the U.S. Food and Drug Administration of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to thirty-three. We believe our current p
12/31/15 - U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem's PLX-PAD Cells for Treatment of Severe Preeclampsia
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced that the U.S. Food and Drug Administration has granted the Company s PLX-PAD cells Orphan Drug Designation in the treatment of severe preeclampsia. Attainment of Orphan Drug Designation for our cells in severe preeclampsia exemplifies o
12/31/15 - United States : FDA approval for famotidine tablets gained by Aurobindo [TendersInfo (India)]
Aurobindo declared that the Food and Drug Administration approved its famotidine tablets in the 20 mg and 40 mg strengths to treat gastroesophageal reflux diesease and active duodenal ulcer. The permitted ANDA is bioequivalent and therapeutically equivalent to Pepcid tablets, 20 mg and 40 mg, from Valeant Pharmaceuticals. Famotidine tablets have an
12/31/14 - Alnylam and The Medicines Company Commence Phase 1 Clinical Trial for ALN-PCSsc [Professional Services Close - Up]
Alnylam Pharmaceuticals has initiated a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia. According to a release, the initiation of this trial has triggered a $10 million milestone from The Medicines Company to Alnylam. Together with The Medicines Company, we look forward to the continued...
12/31/14 - Alnylam Begins Endeavour Phase 3 Clinical Trial with Revusiran (ALN- TTRsc) [Professional Services Close - Up]
Alnylam Pharmaceuticals has initiated the Endeavour Phase 3 clinical trial of revusiran in transthyretin- mediated familial amyloidotic cardiomyopathy. Alnylam is eligible to receive a $25 million milestone from Genzyme when the first patient is dosed in the Endeavour study. Initiation of Endeavour highlights our continued execution on our product.
12/31/14 - Arca Biopharma Activates First Canadian Genetic-AF Clinical Trial Site [Professional Services Close - Up]
ARCA Biopharma has activated the first Genetic-AF clinical trial site in Canada. ARCA plans to activate a total of approximately 60 clinical trial sites in the United States and Canada for the Phase 2 B portion of the trial. Stuart Connolly, MD, Director of the Division of Cardiology at McMaster University in Hamilton, Ontario, Canada, and Co-Chair
12/31/14 - ARIA Widens Sales Turf, NRX Skips A Beat, NDRM Triples On Parkinson's Study
WASHINGTON- Aquinox Pharmaceuticals Inc. has initiated dosing in a phase II clinical trial of AQX-1125 for the treatment of atopic dermatitis. ARIAD Pharmaceuticals Inc. has granted Angelini Pharma exclusive rights to commercialize leukemia drug Iclusig in seven Central and Eastern European countries. The seven countries include Bulgaria, the Czech
12/31/14 - BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing
By a News Reporter-Staff News Editor at Biotech Week BioTime, Inc. announced that its subsidiary ES Cell International Pte. Ltd. and GE Healthcare have signed a set of license agreements through which GEHC received rights to ESI's stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development
12/31/14 - CSL Behring Submits Biologics License Application for FDA Approval of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant...
By a News Reporter-Staff News Editor at Biotech Week CSL Behring announced it has submitted a biologics license application to the United States Food and Drug Administration for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin. Once approved by the FDA, rIX-FP will pr
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415